Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in Int J Urol Retrieve available abstracts of 170 articles: HTML format

Single Articles

July 2024
1. URABE F, Muramoto K, Yanagisawa T, Fukuokaya W, et al
   Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
   Int J Urol. 2024 Jul 19. doi: 10.1111/iju.15546.
   PubMed     Abstract available
   
   
   
2. AIZAWA R, Ishikawa H, Kato M, Shimizu S, et al
   Significance of androgen-deprivation therapy for intermediate- and high-risk prostate cancer treated with high-dose radiotherapy: A literature review.
   Int J Urol. 2024 Jul 17. doi: 10.1111/iju.15535.
   PubMed     Abstract available
   
   
   
3. SUN Q, Du K, Sun S, Liu Y, et al
   Local treatment benefits patients with oligometastatic prostate cancer: A systematic review and meta-analysis.
   Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15540.
   PubMed     Abstract available
   
   
   
4. DELLA CORTE M, Checcucci E
   Editorial Comment on "The role of lipidic balance on erectile dysfunction in prostate cancer patients undergoing robotic surgery".
   Int J Urol. 2024 Jul 9. doi: 10.1111/iju.15543.
   PubMed    
   
   
   
5. DI BELLO F, Fraia A, Pezone G, Colla Ruvolo C, et al
   The role of lipidic balance on erectile dysfunction in prostate cancer patients undergoing robotic surgery.
   Int J Urol. 2024 Jul 3. doi: 10.1111/iju.15516.
   PubMed     Abstract available
   
   
   June 2024
6. TANABE K, Kobayashi S, Tamiya T, Konishi T, et al
   Risk factors for the long-term persistent genitourinary toxicity after stereotactic body radiation therapy for localized prostate cancer: A single-center, retrospective study of 306 patients.
   Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15507.
   PubMed     Abstract available
   
   
   
7. HASHIMOTO K, Kosaka T, Terada N, Kimura T, et al
   Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2023.
   Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15499.
   PubMed     Abstract available
   
   
   
8. KATO M, Shiota M, Kimura T, Hanazawa R, et al
   Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort.
   Int J Urol. 2024;31:662-669.
   PubMed     Abstract available
   
   
   May 2024
9. WATANABE H, Nakane K, Takahara K, Naiki T, et al
   Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
   Int J Urol. 2024 May 19. doi: 10.1111/iju.15498.
   PubMed     Abstract available
   
   
   
10. URABE F
    The relevance of circRNAs in serum of patients undergoing prostate biopsy.
    Int J Urol. 2024;31:581.
    PubMed    
    
    
    
11. SAMIRAE L, Krausewitz P, Alajati A, Kristiansen G, et al
    The relevance of circRNAs in serum of patients undergoing prostate biopsy.
    Int J Urol. 2024;31:578-580.
    PubMed    
    
    
    
12. CHIARELLI G, Davis M, Stephens A, Cirulli GO, et al
    Comparison of patient background between a real-world North American cohort and the Goteborg-2 trial.
    Int J Urol. 2024;31:562-567.
    PubMed     Abstract available
    
    
    
13. ANDO S, Sugihara T, Hinotsu S, Kishino H, et al
    Early recovery of urinary continence after robot-assisted radical prostatectomy is associated with membranous urethra and neurovascular bundle preservation.
    Int J Urol. 2024;31:492-499.
    PubMed     Abstract available
    
    
    April 2024
14. YAMAMOTO Y, Nonomura N
    Editorial Comment to Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
    Int J Urol. 2024 Apr 4. doi: 10.1111/iju.15458.
    PubMed    
    
    
    
15. BLAS L, Shiota M, Tanegashima T, Tsukahara S, et al
    Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy.
    Int J Urol. 2024;31:404-408.
    PubMed     Abstract available
    
    
    March 2024
16. URABE F, Sumiyoshi T, Tashiro K, Goto T, et al
    Prostate cancer and liquid biopsies: Clinical applications and challenges.
    Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15441.
    PubMed     Abstract available
    
    
    
17. GOTO Y
    Editorial Comment on Prostate cancer and liquid biopsies: Clinical applications and challenges.
    Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15456.
    PubMed    
    
    
    
18. KOBAYASHI M, Matsuoka Y, Uehara S, Tanaka H, et al
    Utility of positive core number on MRI-ultrasound fusion targeted biopsy in combination with PI-RADS scores for predicting unexpected extracapsular extension of clinically localized prostate cancer.
    Int J Urol. 2024 Mar 12. doi: 10.1111/iju.15451.
    PubMed     Abstract available
    
    
    
19. GOTO Y
    Editorial Comment on Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
    Int J Urol. 2024 Mar 8. doi: 10.1111/iju.15444.
    PubMed    
    
    
    
20. KAWASE M, Kato D, Tobisawa Y, Iinuma K, et al
    Efficacy and safety of combination neoadjuvant chemo-hormonal therapy and robot-assisted radical prostatectomy for oligometastatic prostate cancer.
    Int J Urol. 2024 Mar 7. doi: 10.1111/iju.15448.
    PubMed    
    
    
    
21. BLAS L, Shiota M, Tanegashima T, Kobayashi S, et al
    Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
    Int J Urol. 2024 Mar 5. doi: 10.1111/iju.15449.
    PubMed    
    
    
    February 2024
22. PARK SJ, Park YJ, Park SM
    Response to comment: Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
    Int J Urol. 2024 Feb 15. doi: 10.1111/iju.15431.
    PubMed    
    
    
    
23. OBINATA D, Takayama K, Inoue S, Takahashi S, et al
    Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
    Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15424.
    PubMed     Abstract available
    
    
    
24. ASAI S, Kobayashi M, Fukuda S, Kimura K, et al
    Significance of atypical nodules upgraded to category 3 in Prostate Imaging Reporting and Data System version 2.1 for prostate cancer diagnosis.
    Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15421.
    PubMed    
    
    
    
25. HIYAMA Y
    Editorial Comment: Proctoscopy following transrectal prostate biopsy can control rectal bleeding after prostate biopsy.
    Int J Urol. 2024;31:143.
    PubMed    
    
    
    January 2024
26. SHOJI S
    Editorial Comment to Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
    Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15406.
    PubMed    
    
    
    
27. LIN YH, Chen YT, Tsai HY
    Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
    Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15401.
    PubMed    
    
    
    
28. MORI K
    Editorial Comment from Dr Mori to Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
    Int J Urol. 2024 Jan 24. doi: 10.1111/iju.15402.
    PubMed    
    
    
    
29. HATANO K
    Editorial Comment on "Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea".
    Int J Urol. 2024 Jan 12. doi: 10.1111/iju.15393.
    PubMed    
    
    
    
30. UKIMURA O
    Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
    PubMed    
    
    
    
31. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
    Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
    PubMed     Abstract available
    
    
    
32. OKIHARA K, Ueda T, Fujihara A, Shiraishi T, et al
    Novel image-guided marker aimed at organ-preserving therapies for prostate cancer.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15389.
    PubMed     Abstract available
    
    
    
33. OKANO K, Miyai K, Mikoshi A, Edo H, et al
    Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15385.
    PubMed     Abstract available
    
    
    
34. DE VELASCO MA, Kura Y, Fujita K, Uemura H, et al
    Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
    Int J Urol. 2024 Jan 2. doi: 10.1111/iju.15378.
    PubMed     Abstract available
    
    
    
35. NAITO Y, Kato M, Nagayama J, Sano Y, et al
    Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate.
    Int J Urol. 2024;31:7-16.
    PubMed     Abstract available
    
    
    December 2023
36. YOKOMIZO A, Shiota M, Morokuma F, Eto M, et al
    GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
    Int J Urol. 2023 Dec 26. doi: 10.1111/iju.15371.
    PubMed     Abstract available
    
    
    
37. PARK SJ, Hong J, Park YJ, Jeong S, et al
    Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
    Int J Urol. 2023 Dec 21. doi: 10.1111/iju.15364.
    PubMed     Abstract available
    
    
    
38. NAKAZONO M, Urabe F, Iwatani K, Imai Y, et al
    Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
    Int J Urol. 2023;30:1147-1154.
    PubMed     Abstract available
    
    
    November 2023
39. YUASA T
    Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
    Int J Urol. 2023;30:1034-1035.
    PubMed    
    
    
    
40. SHIRAISHI K
    Evaluation of sexual function after robot-assisted radical prostatectomy: A farewell to IIEF questionnaire.
    Int J Urol. 2023;30:959-967.
    PubMed     Abstract available
    
    
    
41. BLAS L, Shiota M, Matsumoto T, Hori Y, et al
    Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
    Int J Urol. 2023;30:1029-1034.
    PubMed     Abstract available
    
    
    
42. KOHADA Y, Hieda K, Miyamoto S, Tasaka R, et al
    Retrospective evaluation of the improvement in the urinary status-related quality of life after robot-assisted radical prostatectomy.
    Int J Urol. 2023;30:1020-1027.
    PubMed     Abstract available
    
    
    August 2023
43. MATSUOKA Y, Ueno Y, Uehara S, Tanaka H, et al
    Deep-learning prostate cancer detection and segmentation on biparametric versus multiparametric magnetic resonance imaging: Added value of dynamic contrast-enhanced imaging.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15280.
    PubMed     Abstract available
    
    
    
44. INOUE T, Shin T
    Current magnetic resonance imaging-based diagnostic strategies for prostate cancer.
    Int J Urol. 2023 Aug 17. doi: 10.1111/iju.15281.
    PubMed     Abstract available
    
    
    
45. SHIOTA M, Terada N, Kimura T, Kitamura H, et al
    Differential cancer-specific survival with curative radiotherapy to the prostate for metastatic prostate cancer according to estimated survival by risk group.
    Int J Urol. 2023 Aug 10. doi: 10.1111/iju.15273.
    PubMed    
    
    
    July 2023
46. YASUDA Y, Sakurai M, Numao N, Yamamoto S, et al
    Efficacy and safety profile of olaparib for patients with metastatic castration-resistant prostate cancer: A preliminary report of real-world data in a single institution in Japan.
    Int J Urol. 2023 Jul 26. doi: 10.1111/iju.15261.
    PubMed    
    
    
    
47. YANG X, Tan YG, Gatsinga R, Chen W, et al
    Far from the truth: Real-world treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification.
    Int J Urol. 2023 Jul 11. doi: 10.1111/iju.15243.
    PubMed     Abstract available
    
    
    
48. TANAKA R, Hatakeyama S, Narita S, Sakurai T, et al
    Trends in the use of local intervention for metastatic hormone-naive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2023 Jul 5. doi: 10.1111/iju.15240.
    PubMed     Abstract available
    
    
    
49. ISHII N, Hatakeyama S, Miura H, Tanaka R, et al
    Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
    Int J Urol. 2023;30:572-578.
    PubMed     Abstract available
    
    
    June 2023
50. KATO T, Tohi Y, Honda T, Matsuda I, et al
    A national questionnaire survey of Japanese urologists on treatment perspectives for elderly prostate cancer patients.
    Int J Urol. 2023 Jun 23. doi: 10.1111/iju.15203.
    PubMed     Abstract available
    
    
    
51. SHIEKH M, Houenstein H, Ramahi YO, Shabir U, et al
    Development and validation of nomogram to improve the specificity of multiparametric MRI for clinically significant prostate cancer.
    Int J Urol. 2023 Jun 17. doi: 10.1111/iju.15225.
    PubMed     Abstract available
    
    
    
52. SHOJI S
    Editorial Comment to Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naive men.
    Int J Urol. 2023 Jun 9. doi: 10.1111/iju.15222.
    PubMed    
    
    
    
53. HASHINE K, Yamashita N, Tachou T, Kan M, et al
    Radical prostatectomy trends between 2010 and 2020 in Ehime, Japan, identified using data from the Medical Investigation Cancer Network (MICAN) study.
    Int J Urol. 2023;30:547-553.
    PubMed     Abstract available
    
    
    
54. SOMA T, Fukuda S, Matsuyama Y, Ikeda R, et al
    Peritoneal closure and the processus vaginalis transection method to prevent inguinal hernia after robot-assisted radical prostatectomy.
    Int J Urol. 2023;30:532-538.
    PubMed     Abstract available
    
    
    May 2023
55. MIYAZAWA Y, Hori K, Tsuji Y, Sekine Y, et al
    The utility of the [-2]pro-prostate-specific antigen level as a prognostic marker in patients with castration-resistant prostate cancer treated with enzalutamide.
    Int J Urol. 2023 May 31. doi: 10.1111/iju.15212.
    PubMed     Abstract available
    
    
    
56. TEISHIMA J
    Editorial Comment to "Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naive men".
    Int J Urol. 2023 May 7. doi: 10.1111/iju.15202.
    PubMed    
    
    
    
57. GOTO Y, Utsumi T, Maruo M, Kurozumi A, et al
    Development and validation of novel nomogram to identify the candidates for extended pelvic lymph node dissection for prostate cancer patients in the robotic era.
    Int J Urol. 2023 May 2. doi: 10.1111/iju.15195.
    PubMed     Abstract available
    
    
    April 2023
58. BLAS L, Shiota M, Tsukahara S, Goto S, et al
    Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naive men.
    Int J Urol. 2023 Apr 20. doi: 10.1111/iju.15188.
    PubMed     Abstract available
    
    
    
59. LEE K, Shiota M, Takamatsu D, Ushijima M, et al
    Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy.
    Int J Urol. 2023;30:340-346.
    PubMed     Abstract available
    
    
    March 2023
60. YOSHIDA S, Takahara T, Tanaka H, Yokoyama M, et al
    The role of prostate-specific antigen changes in predicting overall survival after progressive-site directed therapy for oligoprogressive castration-resistant prostate cancer.
    Int J Urol. 2023 Mar 31. doi: 10.1111/iju.15185.
    PubMed    
    
    
    February 2023
61. KRAUSEWITZ P, Farzat M, Ellinger J, Ritter M, et al
    Omitting routine cystography after RARP: Analysis of complications and readmission rates in suprapubic and transurethral drained patients.
    Int J Urol. 2023;30:211-218.
    PubMed     Abstract available
    
    
    
62. FURUMIDO J, Maishi N, Yanagawa-Matsuda A, Kikuchi H, et al
    Stroma biglycan expression can be a prognostic factor in prostate cancers.
    Int J Urol. 2023;30:147-154.
    PubMed     Abstract available
    
    
    January 2023
63. KIJIMA T
    Editorial Comment to Novel quantitative software for automatically excluding red bone marrow on whole-body magnetic resonance imaging in patients with metastatic prostate cancer: A pilot study.
    Int J Urol. 2023 Jan 24. doi: 10.1111/iju.15147.
    PubMed    
    
    
    
64. KISHIDA T
    Editorial Comment on a national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer.
    Int J Urol. 2023 Jan 18. doi: 10.1111/iju.15142.
    PubMed    
    
    
    
65. YAMAGUCHI H, Kato T, Ishikawa Y, Takemasa K, et al
    Safety of hydrogel spacers for rectal wall protection in patients with prostate cancer: A retrospective analysis of 200 consecutive cases.
    Int J Urol. 2023 Jan 18. doi: 10.1111/iju.15140.
    PubMed     Abstract available
    
    
    
66. KITAMURA K, China T, Nagata M, Isotani S, et al
    Prediction of recovery time of urinary incontinence following robot-assisted laparoscopic prostatectomy.
    Int J Urol. 2023;30:77-82.
    PubMed     Abstract available
    
    
    December 2022
67. MATSUMOTO R
    Editorial Comment to "A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer".
    Int J Urol. 2022 Dec 21. doi: 10.1111/iju.15127.
    PubMed    
    
    
    
68. KOHADA Y, Satani N, Kaiho Y, Iwamura H, et al
    Novel quantitative software for automatically excluding red bone marrow on whole-body magnetic resonance imaging in patients with metastatic prostate cancer: A pilot study.
    Int J Urol. 2022 Dec 20. doi: 10.1111/iju.15124.
    PubMed     Abstract available
    
    
    
69. OGASAWARA N, Nakiri M, Kurose H, Ueda K, et al
    Sarcopenia and excess visceral fat accumulation negatively affect early urinary function after I-125 low-dose-rate brachytherapy for localized prostate cancer.
    Int J Urol. 2022 Dec 15. doi: 10.1111/iju.15120.
    PubMed     Abstract available
    
    
    
70. KADONO Y
    Editorial Comment to Predictive factors of de novo overactive bladder in clinically localized prostate cancer patients after robot-assisted radical prostatectomy.
    Int J Urol. 2022 Dec 14. doi: 10.1111/iju.15074.
    PubMed    
    
    
    
71. WATANABE K, Otsuka A, Sano A, Sato R, et al
    Predictive factors of de novo overactive bladder in clinically localized prostate cancer patients after robot-assisted radical prostatectomy.
    Int J Urol. 2022 Dec 13. doi: 10.1111/iju.15060.
    PubMed     Abstract available
    
    
    
72. NARUKAWA T, Fujihara A, Ochiai A, Okihara K, et al
    Role of hydrogel spacer to protect the rectum from thermal injury in focal therapy of prostate cancer: Preclinical study in cadaver model.
    Int J Urol. 2022 Dec 9. doi: 10.1111/iju.15062.
    PubMed    
    
    
    
73. TANAKA N, Nakai Y, Asakawa I, Yamaki K, et al
    Local dose (biologically effective dose >/=180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapy.
    Int J Urol. 2022;29:1560-1568.
    PubMed     Abstract available
    
    
    
74. OHARA E, Kawamorita N, Satake Y, Kaiho Y, et al
    Minimal residual membranous urethral length and membranous urethral length predict poor recovery from incontinence after robot-assisted radical prostatectomy and after open radical prostatectomy.
    Int J Urol. 2022;29:1517-1523.
    PubMed     Abstract available
    
    
    
75. OJIMA K, Horiguchi A, Shinchi M, Tabei T, et al
    Transperineal bulbovesical anastomosis for extensive posterior urethral stenoses after treatment of prostatic disease.
    Int J Urol. 2022;29:1511-1516.
    PubMed     Abstract available
    
    
    
76. WASHINO S, Ito K, Miyagawa T
    Prostate-specific antigen level, biopsy grade group, and tumor-capsular contact length on magnetic resonance imaging are independently associated with an extraprostatic extension.
    Int J Urol. 2022;29:1455-1461.
    PubMed     Abstract available
    
    
    November 2022
77. KATO T, Tohi Y, Honda T, Matsuda I, et al
    A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer.
    Int J Urol. 2022 Nov 22. doi: 10.1111/iju.15102.
    PubMed     Abstract available
    
    
    
78. ARAI M, Kosaka T, Yasumizu Y, Takeda T, et al
    Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer.
    Int J Urol. 2022 Nov 14. doi: 10.1111/iju.15098.
    PubMed     Abstract available
    
    
    
79. TERADA N, Sawada A, Kawanishi H, Fujimoto T, et al
    The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan.
    Int J Urol. 2022 Nov 14. doi: 10.1111/iju.15097.
    PubMed     Abstract available
    
    
    
80. TOBU S, Noguchi M
    Long-term outcomes of Blocksom vesicostomy for elderly patients with chronic urinary retention.
    Int J Urol. 2022;29:1357-1361.
    PubMed     Abstract available
    
    
    October 2022
81. YOSHIDA S, Takahara T, Arita Y, Toda K, et al
    Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy.
    Int J Urol. 2022 Oct 31. doi: 10.1111/iju.15090.
    PubMed     Abstract available
    
    
    
82. SHIMBO M, Ohyama T, Endo F, Komatsu K, et al
    Simplified approach to the medial internal iliac region using a uretero-hypogastric nerve fascia development procedure for extended pelvic lymph node dissection during robot-assisted radical prostatectomy for high-risk prostate cancer.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15082.
    PubMed     Abstract available
    
    
    
83. MATSUMOTO T, Hori Y, Shiota M, Blas L, et al
    Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15078.
    PubMed     Abstract available
    
    
    
84. HORI S, Nakai Y, Tachibana A, Omori C, et al
    Clinical significance of limited and extended pelvic lymph node dissection during robot-assisted radical prostatectomy for patients with localized prostate cancer: A retrospective, propensity score matching analysis.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15075.
    PubMed     Abstract available
    
    
    
85. FUKUHARA S, Nonomura N
    Editorial Comment to Sperm cryopreservation before definitive therapy for early-stage prostate cancer: A single institution experience.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15079.
    PubMed    
    
    
    
86. VAN EECKE H, Devos G, Vansevenant B, Vander Stichele A, et al
    Defining the optimal template of salvage lymph node dissection for unilateral pelvic nodal recurrence of prostate cancer following radical prostatectomy.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15066.
    PubMed     Abstract available
    
    
    
87. YAMAMICHI G, Kato T, Yumiba S, Tomiyama E, et al
    Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15063.
    PubMed     Abstract available
    
    
    
88. MIYOSHI Y, Kawahara T, Kuroda S, Takeshima T, et al
    Sperm cryopreservation before definitive therapy for early-stage prostate cancer: A single institution experience.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15047.
    PubMed    
    
    
    
89. HINATA N, Yamaguchi R, Kusuhara Y, Kanayama H, et al
    Hinotori Surgical Robot System, a novel robot-assisted surgical platform: Preclinical and clinical evaluation.
    Int J Urol. 2022;29:1213-1220.
    PubMed     Abstract available
    
    
    
90. ISHIKAWA H, Hiroshima Y, Kanematsu N, Inaniwa T, et al
    Carbon-ion radiotherapy for urological cancers.
    Int J Urol. 2022;29:1109-1119.
    PubMed     Abstract available
    
    
    
91. TSUBOUCHI K, Gunge N, Tominaga K, Matsuzaki H, et al
    Efficacy of the opened legs position for protecting against postoperative rhabdomyolysis after robot-assisted radical prostatectomy: A propensity score-matched analysis of perioperative outcomes.
    Int J Urol. 2022;29:1132-1138.
    PubMed     Abstract available
    
    
    
92. HAYASHI T, Hinata N
    Current status and future prospects of antibody-drug conjugates in urological malignancies.
    Int J Urol. 2022;29:1100-1108.
    PubMed     Abstract available
    
    
    September 2022
93. YAMAMOTO Y, Ishii M, Yoshimura A, Hayashi T, et al
    Efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer: A single-center study in Japan.
    Int J Urol. 2022 Sep 28. doi: 10.1111/iju.15052.
    PubMed     Abstract available
    
    
    
94. GOTO Y
    Editorial Comment to miRNAs in prostate cancer: Intercellular and extracellular communications.
    Int J Urol. 2022 Sep 20. doi: 10.1111/iju.15058.
    PubMed    
    
    
    
95. URABE F, Yamamoto Y, Kimura T
    miRNAs in prostate cancer: Intercellular and extracellular communications.
    Int J Urol. 2022 Sep 19. doi: 10.1111/iju.15043.
    PubMed     Abstract available
    
    
    
96. YADAV S, Kumar A
    Editorial Comment by Dr Yadav and Dr Kumar to 'Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy'.
    Int J Urol. 2022 Sep 12. doi: 10.1111/iju.15032.
    PubMed    
    
    
    
97. KOSHIRO N, Nakajima K, Oyama M, Kaneko G, et al
    Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer.
    Int J Urol. 2022 Sep 7. doi: 10.1111/iju.15022.
    PubMed     Abstract available
    
    
    August 2022
98. SAKAMOTO S
    Editorial Comment on "Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naive prostate cancer in Japan: An interim analysis of the J-ROCK study".
    Int J Urol. 2022 Aug 29. doi: 10.1111/iju.15016.
    PubMed    
    
    
    
99. UEMURA H, Matsumoto R, Mizokami A, Miyake H, et al
    Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naive prostate cancer in Japan: An interim analysis of the J-ROCK study.
    Int J Urol. 2022 Aug 26. doi: 10.1111/iju.14993.
    PubMed     Abstract available
    
    
    
100. GOTO Y
     Editorial comment to Trends in primary treatment for localized prostate cancer according to the availability of treatment modalities and the impact of introducing robotic surgery.
     Int J Urol. 2022 Aug 24. doi: 10.1111/iju.15017.
     PubMed    
     
     
     
101. KATO M
     Editorial comments on Patient-reported outcomes of a phase II neoadjuvant Apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
     Int J Urol. 2022 Aug 24. doi: 10.1111/iju.15013.
     PubMed    
     
     
     
102. URABE F
     Editorial Comment from Dr. Urabe to Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy.
     Int J Urol. 2022 Aug 24. doi: 10.1111/iju.15011.
     PubMed    
     
     
     
103. YANG X, Allen JC, Aslim EJ, Tay KJ, et al
     Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
     Int J Urol. 2022 Aug 24. doi: 10.1111/iju.14994.
     PubMed     Abstract available
     
     
     
104. SASAKI T, Matsumoto R, Higashi S, Kato M, et al
     Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy.
     Int J Urol. 2022 Aug 24. doi: 10.1111/iju.14990.
     PubMed     Abstract available
     
     
     
105. FUJIHARA A, Ukimura O
     Focal therapy of localized prostate cancer.
     Int J Urol. 2022 Aug 22. doi: 10.1111/iju.14991.
     PubMed     Abstract available
     
     
     
106. HORI S, Nakai Y, Tomizawa M, Morizawa Y, et al
     Trends in primary treatment for localized prostate cancer according to the availability of treatment modalities and the impact of introducing robotic surgery.
     Int J Urol. 2022 Aug 17. doi: 10.1111/iju.15003.
     PubMed     Abstract available
     
     
     
107. KAWAHARA T, Miyoshi Y, Ninomiya S, Sato M, et al
     Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study.
     Int J Urol. 2022 Aug 17. doi: 10.1111/iju.15008.
     PubMed     Abstract available
     
     
     
108. ZHANG Y, Song XL, Yu B, Foong LC, et al
     TP53 loss-of-function causes vulnerability to autophagy inhibition in aggressive prostate cancer.
     Int J Urol. 2022 Aug 17. doi: 10.1111/iju.15021.
     PubMed     Abstract available
     
     
     July 2022
109. KIMURA K, Kitajima K, Kawanaka Y, Yokoyama H, et al
     Evaluation of (11) C-choline positron emission tomography/computed tomography for determining treatment response in castration-resistant prostate cancer patients.
     Int J Urol. 2022 Jul 25. doi: 10.1111/iju.14992.
     PubMed     Abstract available
     
     
     
110. KATO T, Yokomizo A, Matsumoto R, Tohi Y, et al
     Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study.
     Int J Urol. 2022 Jul 19. doi: 10.1111/iju.14977.
     PubMed     Abstract available
     
     
     June 2022
111. KASHIWAGI E, Shiota M, Naganuma H, Monji K, et al
     Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer.
     Int J Urol. 2022 Jun 18. doi: 10.1111/iju.14953.
     PubMed     Abstract available
     
     
     
112. KONISHI T, Washino S, Okochi T, Miyagawa T, et al
     Combination of biparametric magnetic resonance imaging with prostate-specific antigen density to stratify the risk of significant prostate cancer: Initial biopsy and long-term follow-up results.
     Int J Urol. 2022 Jun 13. doi: 10.1111/iju.14948.
     PubMed     Abstract available
     
     
     May 2022
113. NARITA S, Terada N, Nomura K, Sakamoto S, et al
     Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.
     Int J Urol. 2022 May 25. doi: 10.1111/iju.14938.
     PubMed     Abstract available
     
     
     
114. BANNO T, Nakamura K, Kaneda Y, Ozaki A, et al
     Detection rate and variables associated with incidental prostate cancer by holmium laser enucleation of the prostate.
     Int J Urol. 2022 May 18. doi: 10.1111/iju.14917.
     PubMed     Abstract available
     
     
     
115. SEKITO T, Sadahira T
     Editorial Comment to Detection rate and variables associated with incidental prostate cancer by holmium laser enucleation of the prostate.
     Int J Urol. 2022 May 18. doi: 10.1111/iju.14934.
     PubMed    
     
     
     
116. TAVERNA G, Grizzi F, Tidu L, Bax C, et al
     Accuracy of a new electronic nose for prostate cancer diagnosis in urine samples.
     Int J Urol. 2022 May 9. doi: 10.1111/iju.14912.
     PubMed     Abstract available
     
     
     April 2022
117. FUJITA K, Matsushita M, Banno E, De Velasco MA, et al
     Gut microbiome and prostate cancer.
     Int J Urol. 2022 Apr 6. doi: 10.1111/iju.14894.
     PubMed     Abstract available
     
     
     
118. ZANG Z, Wang Z, Chiong E
     Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-c
     Int J Urol. 2022 Apr 5. doi: 10.1111/iju.14891.
     PubMed    
     
     
     
119. KATO M
     Editorial Comment to Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer.
     Int J Urol. 2022 Apr 2. doi: 10.1111/iju.14890.
     PubMed    
     
     
     March 2022
120. KAMITANI N, Miyaji Y, Tamada T, Yoden E, et al
     Feasibility of magnetic resonance imaging-ultrasound guided high-dose-rate brachytherapy for localized prostate cancer: Preliminary results from a prospective study.
     Int J Urol. 2022 Mar 30. doi: 10.1111/iju.14880.
     PubMed     Abstract available
     
     
     
121. SHIOTA M
     Editorial Comment to Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
     Int J Urol. 2022 Mar 16. doi: 10.1111/iju.14864.
     PubMed    
     
     
     
122. UEMURA H, Arai G, Uemura H, Suzuki H, et al
     Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III
     Int J Urol. 2022 Mar 15. doi: 10.1111/iju.14843.
     PubMed     Abstract available
     
     
     
123. SASAKI D, Hatakeyama S, Tanaka T, Okamoto T, et al
     Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.
     Int J Urol. 2022 Mar 13. doi: 10.1111/iju.14860.
     PubMed    
     
     
     
124. NARITA T, Hatakeyama S, Ohyama C
     Editorial Comment to Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
     Int J Urol. 2022 Mar 1. doi: 10.1111/iju.14849.
     PubMed    
     
     
     February 2022
125. QIAN Y, Liu X, Feng Y, Li X, et al
     Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer.
     Int J Urol. 2022 Feb 25. doi: 10.1111/iju.14830.
     PubMed     Abstract available
     
     
     
126. TAMURA K, Matsushita Y, Watanabe H, Motoyama D, et al
     Limited impact of erectile function on health-related quality of life in Japanese men undergoing robot-assisted radical prostatectomy.
     Int J Urol. 2022 Feb 17. doi: 10.1111/iju.14826.
     PubMed     Abstract available
     
     
     
127. LEE W, Lim B, Kyung YS, Kim CS, et al
     Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
     Int J Urol. 2022 Feb 8. doi: 10.1111/iju.14799.
     PubMed     Abstract available
     
     
     
128. TANAKA T, Hatakeyama S, Noro D, Togashi K, et al
     Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
     Int J Urol. 2022 Feb 7. doi: 10.1111/iju.14817.
     PubMed    
     
     
     January 2022
129. YANG Y, Liu Z, Wang Q, Chang K, et al
     Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer.
     Int J Urol. 2022 Jan 31. doi: 10.1111/iju.14801.
     PubMed     Abstract available
     
     
     
130. BLAS L, Shiota M, Nagakawa S, Tsukahara S, et al
     Validation of models predicting lymph node involvement probability in patients with prostate cancer.
     Int J Urol. 2022 Jan 31. doi: 10.1111/iju.14802.
     PubMed     Abstract available
     
     
     
131. NAGUMO Y, Onozawa M, Kojima T, Terada N, et al
     Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
     Int J Urol. 2022 Jan 25. doi: 10.1111/iju.14793.
     PubMed     Abstract available
     
     
     
132. MOROZUMI K, Mitsuzuka K, Narita S, Takahashi M, et al
     Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score >/=8.
     Int J Urol. 2022 Jan 18. doi: 10.1111/iju.14781.
     PubMed     Abstract available
     
     
     
133. HASEGAWA M, Yamada K, Shigeta K, Yuzuriha S, et al
     How long should urologists observe patients with prostate cancer after radical prostatectomy? Weibull analysis.
     Int J Urol. 2022 Jan 4. doi: 10.1111/iju.14774.
     PubMed     Abstract available
     
     
     
134. YAMASHITA S, Kawabata H, Deguchi R, Ueda Y, et al
     Myosteatosis as a novel predictor of urinary incontinence after robot-assisted radical prostatectomy.
     Int J Urol. 2022;29:34-40.
     PubMed     Abstract available
     
     
     December 2021
135. TAKAHARA K, Naiki T, Ito T, Nakane K, et al
     Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.
     Int J Urol. 2021 Dec 4. doi: 10.1111/iju.14754.
     PubMed     Abstract available
     
     
     November 2021
136. WURNSCHIMMEL C, Wenzel M, Chierigo F, Simone Flammia R, et al
     Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
     Int J Urol. 2021 Nov 17. doi: 10.1111/iju.14743.
     PubMed    
     
     
     
137. OWARI T, Tanaka N, Nakai Y, Miyake M, et al
     Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer.
     Int J Urol. 2021 Nov 11. doi: 10.1111/iju.14738.
     PubMed     Abstract available
     
     
     
138. SO WZ, Wang Z, Tiong HY
     Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
     Int J Urol. 2021 Nov 5. doi: 10.1111/iju.14741.
     PubMed    
     
     
     October 2021
139. YUASA T
     Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
     Int J Urol. 2021 Oct 6. doi: 10.1111/iju.14725.
     PubMed    
     
     
     
140. AKAKURA K
     Editorial Comment to External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
     Int J Urol. 2021 Oct 4. doi: 10.1111/iju.14723.
     PubMed    
     
     
     
141. YAMAMOTO S
     Editorial Comment to Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
     Int J Urol. 2021;28:1045-1046.
     PubMed    
     
     
     
142. FUKUNAGA A, Maejima A, Shinoda Y, Matsui Y, et al
     Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
     Int J Urol. 2021;28:1039-1045.
     PubMed     Abstract available
     
     
     
143. TEO XL, Lim SK
     Targeting the vessels first: A modified surgical technique for prostatic paraganglioma.
     Int J Urol. 2021;28:1073-1074.
     PubMed    
     
     
     September 2021
144. WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
     External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
     Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14701.
     PubMed     Abstract available
     
     
     
145. SHIOTA M, Blas L, Kobayashi S, Matsumoto T, et al
     Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
     Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14702.
     PubMed     Abstract available
     
     
     
146. KADONO Y
     Editorial Comment to Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
     Int J Urol. 2021 Sep 8. doi: 10.1111/iju.14690.
     PubMed    
     
     
     
147. COLARIETI A, Thiruchelvam N, Barrett T
     Evaluation of image-based prognostic parameters of post-prostatectomy urinary incontinence: A literature review.
     Int J Urol. 2021;28:890-897.
     PubMed     Abstract available
     
     
     August 2021
148. MAESAKA F, Tanaka N, Nakai Y, Asakawa I, et al
     Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
     Int J Urol. 2021 Aug 10. doi: 10.1111/iju.14667.
     PubMed     Abstract available
     
     
     
149. NAKAI Y, Tanaka N, Fujii T, Miyake M, et al
     Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10 839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015.
     Int J Urol. 2021 Aug 5. doi: 10.1111/iju.14666.
     PubMed     Abstract available
     
     
     July 2021
150. MIYAMOTO S, Goto K, Honda Y, Terada H, et al
     Tumor contact length of prostate cancer determined by a three-dimensional method on multiparametric magnetic resonance imaging predicts extraprostatic extension and biochemical recurrence.
     Int J Urol. 2021 Jul 5. doi: 10.1111/iju.14633.
     PubMed     Abstract available
     
     
     
151. SHIGEMURA K, Fujisawa M
     Prevention and management of infectious complications in prostate biopsy: A review.
     Int J Urol. 2021;28:714-719.
     PubMed     Abstract available
     
     
     June 2021
152. SUGIHARA T
     Editorial Comment to Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
     Int J Urol. 2021 Jun 24. doi: 10.1111/iju.14620.
     PubMed    
     
     
     
153. NAKAJIMA K, Mizokami A, Matsuyama H, Ichikawa T, et al
     Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
     Int J Urol. 2021 Jun 19. doi: 10.1111/iju.14614.
     PubMed     Abstract available
     
     
     
154. ANDELA CD, Matte R, Jazet IM, Zonneveld WC, et al
     Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review.
     Int J Urol. 2021 Jun 14. doi: 10.1111/iju.14596.
     PubMed     Abstract available
     
     
     
155. KIMURA Y, Honda M, Teraoka S, Yumioka T, et al
     Impact of penile rehabilitation with phosphodiesterase-5 inhibitors on recovery of erectile function in patients undergoing robot-assisted radical prostatectomy: A propensity score-matched analysis.
     Int J Urol. 2021;28:637-642.
     PubMed     Abstract available
     
     
     
156. TAGUCHI S, Morikawa T, Shibahara J, Fukuhara H, et al
     Prognostic significance of tertiary Gleason pattern in the contemporary era of Gleason grade grouping: A narrative review.
     Int J Urol. 2021;28:614-621.
     PubMed     Abstract available
     
     
     May 2021
157. STOLZENBACH LF, Deuker M, Colla-Ruvolo C, Nocera L, et al
     Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study.
     Int J Urol. 2021 May 28. doi: 10.1111/iju.14586.
     PubMed     Abstract available
     
     
     
158. CHIKAMATSU S, Shiota M, Onozawa M, Hinotsu S, et al
     Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database.
     Int J Urol. 2021 May 24. doi: 10.1111/iju.14605.
     PubMed     Abstract available
     
     
     
159. INOUE T, Yoshimura K, Terada N, Tsukino H, et al
     Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study).
     Int J Urol. 2021 May 18. doi: 10.1111/iju.14590.
     PubMed     Abstract available
     
     
     
160. WURNSCHIMMEL C, Wenzel M, Colla Ruvolo C, Nocera L, et al
     Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
     Int J Urol. 2021 May 15. doi: 10.1111/iju.14595.
     PubMed     Abstract available
     
     
     
161. IGUCHI T, Kimura G, Fukasawa S, Suzuki H, et al
     Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
     Int J Urol. 2021 May 6. doi: 10.1111/iju.14568.
     PubMed     Abstract available
     
     
     
162. CLAPS F, Ramirez-Backhaus M, Mir Maresma MC, Gomez-Ferrer A, et al
     Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy.
     Int J Urol. 2021;28:566-572.
     PubMed     Abstract available
     
     
     
163. MATTI B, Zargar-Shoshtari K
     Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population.
     Int J Urol. 2021;28:578-583.
     PubMed     Abstract available
     
     
     
164. LOW AW, Chen K, Tan YG, Ng TK, et al
     Ambulatory robot-assisted laparoscopic radical prostatectomy with extended recovery by total extraperitoneal approach.
     Int J Urol. 2021;28:561-565.
     PubMed     Abstract available
     
     
     April 2021
165. YOSHIDA S, Fujii Y
     Editorial Comment to Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
     Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14578.
     PubMed    
     
     
     
166. AIZAWA R, Takayama K, Nakamura K, Ogata T, et al
     Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
     Int J Urol. 2021 Apr 2. doi: 10.1111/iju.14567.
     PubMed     Abstract available
     
     
     
167. TATENUMA T, Makiyama K, Ito Y, Muraoka K, et al
     Correlation of urinary loss rate after catheter removal and long-term urinary continence after robot-assisted laparoscopic radical prostatectomy.
     Int J Urol. 2021;28:440-443.
     PubMed     Abstract available
     
     
     
168. HAGA N, Miyazaki T, Tsubouchi K, Okabe Y, et al
     Comprehensive approach for preserving cavernous nerves and erectile function after radical prostatectomy in the era of robotic surgery.
     Int J Urol. 2021;28:360-368.
     PubMed     Abstract available
     
     
     February 2021
169. KUSHWAHA B, Devi A, Maikhuri JP, Rajender S, et al
     Inflammation driven tumor-like signaling in prostatic epithelial cells by sexually transmitted Trichomonas vaginalis.
     Int J Urol. 2021;28:225-240.
     PubMed     Abstract available
     
     
     January 2021
170. FALAGARIO UG, Lantz A, Jambor I, Martini A, et al
     Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.
     Int J Urol. 2021;28:47-52.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.